CRISPR Therapeutics (CRSP) incurred a loss of $1.49 per share in the second quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of $1.37. In the year-ago period, the company had incurred a loss of 98 cents per share. The company's total revenues, though negligible, were entirely from grant revenues, which were $0.5 million in the second quarter. The reported figure significantly missed the Zacks Consensus Estimate of $8 million. In the year-ago quarter, the company generated collabo ...